2 studies were found.

1.		Recruiting	BB-10901 in Treating Patients With Recurrent or Refractory Lung Cancer, Metastatic Carcinoid Tumor, or Other Solid Tumors Conditions: adult solid tumor; gastrointestinal carcinoid tumor; Neuroendocrine Carcinoma; Non-small cell lung cancer; pulmonary carcinoid tumor; ...
2.		Recruiting	A Phase I, Open-Label, Dose Escalation Study of Weekly Dosing with BB-10901, followed by a Phase II Efficacy Expansion Condition: Small Cell Lung Cancer